Legal & General Group’s Enliven Therapeutics ELVN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $646K | Buy |
32,225
+11,058
| +52% | +$222K | ﹤0.01% | 2376 |
|
|
2025
Q1 | $417K | Buy |
21,167
+27
| +0.1% | +$532 | ﹤0.01% | 2451 |
|
|
2024
Q4 | $476K | Buy |
21,140
+812
| +4% | +$18.3K | ﹤0.01% | 2473 |
|
|
2024
Q3 | $519K | Buy |
20,328
+131
| +0.6% | +$3.35K | ﹤0.01% | 2451 |
|
|
2024
Q2 | $472K | Sell |
20,197
-448
| -2% | -$10.5K | ﹤0.01% | 2433 |
|
|
2024
Q1 | $363K | Buy |
20,645
+980
| +5% | +$17.2K | ﹤0.01% | 2548 |
|
|
2023
Q4 | $272K | Hold |
19,665
| – | – | ﹤0.01% | 2648 |
|
|
2023
Q3 | $269K | Buy |
19,665
+1,610
| +9% | +$22K | ﹤0.01% | 2648 |
|
|
2023
Q2 | $369K | Buy |
+18,055
| New | +$369K | ﹤0.01% | 2563 |
|
|
2021
Q2 | – | Sell |
-244
| Closed | -$8K | – | 3536 |
|
|
2021
Q1 | $8K | Buy |
244
+30
| +14% | +$984 | ﹤0.01% | 3426 |
|
|
2020
Q4 | $19K | Buy |
214
+58
| +37% | +$5.15K | ﹤0.01% | 3108 |
|
|
2020
Q3 | $13K | Sell |
156
-48
| -24% | -$4K | ﹤0.01% | 3121 |
|
|
2020
Q2 | $22K | Buy |
+204
| New | +$22K | ﹤0.01% | 3025 |
|